

# Gemini Stock Analysis Report

---

Based on the attached "Stock Detailed Analysis Report" for **ZYDUSLIFE.NS** (generated 2026-01-24), here is the positional trading analysis.

## Step 1: Audit the Data

- **Data Present:**

- Multi-timeframe price charts (Weekly, Daily, 15-min).
- Moving Averages (EMA 20, 50, 200).
- Momentum Indicators (RSI, MACD).
- Trend Indicators (Supertrend, Bollinger Bands).
- Relative Strength (RS) Analysis vs. Sector.
- Volume Analysis and Fundamental Snapshots.

- **Data Missing:**

- Specific delivery percentage data (to confirm accumulation vs. churn).
- Option Chain data (to identify Open Interest resistance levels).

- **Confidence Level: High.** The report provides a comprehensive technical suite sufficient for intermediate-term trend analysis.

- *Note: The report date is January 2026. This analysis treats the data as current per the document's timeframe.*

## Step 2: Analyze the Setup

- **Trend Structure (Bearish):** The stock is in a confirmed **Strong Downtrend**.

- Price (882.00) is below all key EMAs ( $20 < 50 < 200$ ). The 200 EMA (944.76) is sloping downward, acting as a major dynamic resistance "ceiling."
- The Supertrend is signaling **SELL** with resistance at 920.17.
- The Multi-Timeframe analysis (Page 20) confirms a "**Downtrend**" across Weekly, Daily, and 15-min intervals.

- **Momentum (Weak):**

- **RSI:** Currently at 40.10. It is in a bearish zone (below 50) but not yet deeply oversold (below 30), suggesting there is still room for downside movement.
- **MACD:** The histogram is negative, and the Signal Line is above the MACD Line (**Bearish**).
- **Relative Strength:** The stock has an RS Score of 47.5/100 and is classified as "Underperforming" the Pharma sector (Page 5).

- **Volatility Signals:**

- A **Bearish Breakout** from a volatility squeeze was identified on 2026-01-09 (Page 14). This usually initiates a sustained move in the direction of the breakout (downward).
- Recent "Distribution Days" (Page 18) indicate institutional selling pressure in January 2026.

## Step 3: Formulate the Recommendation

**Should you enter this stock now? NO.**

**Reasoning:** The stock is trying to catch a falling knife. Buying now fights the dominant trend, weak momentum, and overhead supply. There is no confluence of indicators suggesting a bottom is in place yet. The probability of a 5-15% upside is low until the market structure changes.

**Conditional Plan (Reversal Setup):** To consider a long position, the stock must prove that the downtrend is

# Gemini Stock Analysis Report

---

exhausted by reclaiming key dynamic resistance levels.

- **Condition to Buy:** The stock must close **above the Daily Supertrend (920.17)**. Ideally, a close above the **200 EMA (approx. 945)** is the safest confirmation for a positional trade, but an aggressive entry can be taken on the Supertrend reversal.
- **Entry Price:** INR **925.00** (Wait for a daily candle close above 921 to confirm strength and clear the 50 EMA).
- **Stop Loss:** INR **875.00** (Below the recent swing low support).
- **Take Profit:** INR **1,015.00** (Targeting the previous breakdown structure and psychological resistance).

*Risk Profile for Conditional Trade:* This setup offers roughly a 1:2 Risk/Reward ratio (50 points risk vs. 90 points reward). Do not enter if the price remains below 920.

## News & Analyst Targets

Here is the latest stock research and information for **Zydus Lifesciences (ZYDUSLIFE)** as of **Sunday, January 25, 2026**.

### 1) Latest News for ZYDUSLIFE This Week (Jan 19 - Jan 25, 2026)

The week has been eventful for Zydus Lifesciences with significant regulatory and product launch updates:

**USFDA Inspection at Ankleshwar Concludes (Jan 24, 2026):** The USFDA completed an inspection of the company's **Unit-2 manufacturing plant at Ankleshwar, Gujarat**, which took place from January 19 to January 23, 2026. The inspection closed with **3 observations**. Importantly, the company clarified that there were **no data integrity-related observations**, which is generally viewed as a relief by investors compared to more severe regulatory actions.

**Launch of World's First Nivolumab Biosimilar (Jan 22, 2026):** Zydus launched '**Tishtha**', the world's first biosimilar of the cancer immunotherapy drug *Nivolumab* (brand name Opdivo), in India.

- **Impact:** This drug is used to treat multiple types of cancers. Zydus has priced it at approximately **1/4th the cost** of the innovator drug, aiming to make critical cancer therapy more affordable and accessible.

**Brokerage Upgrade on Specialty Business Outlook (Jan 20, 2026):** Following the recent USFDA approval of **Zycubo** (for Menkes disease), brokerage firm **Systematix Institutional Equities** upgraded the stock to a '**Buy**' rating this week, citing strong growth catalysts in the US specialty segment.

---

### 2) Upgrade or Downgrade from Brokerages

#### Systematix Institutional Equities (Upgrade):

- **Action:** Upgraded to **BUY**.
- **Rationale:** The firm cites the USFDA approval of *Zycubo* (marketed by subsidiary Sentyln Therapeutics) as a key earnings driver. They believe this approval significantly improves the outlook for Zydus's US specialty business and revenue potential.

# Gemini Stock Analysis Report

---

## Macquarie (Recent Maintained):

- **Action:** Maintained **BUY** (Reported mid-January).
  - **View:** Continues to see upside potential, setting a target higher than the current market price.
- 

## 3) Other News Impacting ZYDUSLIFE

**Menkes Disease Drug (Zycubo) Approval:** Although announced just prior to this week (mid-January), the **USFDA approval of Zycubo** (copper histidinate) remains a dominant driver. It is the first and only FDA-approved treatment for Menkes disease. This is a high-value product for the company's US subsidiary, Sentyln Therapeutics, and is expected to aid profitability by FY28.

**Eltrombopag Tablets Approval:** The company recently received final approval from the USFDA to market **Eltrombopag Tablets** (generic for Promacta), used to treat low blood platelet counts. This opens up a significant market opportunity (estimated market size ~\$1.2 billion) and strengthens their US generic portfolio.

**Positive Sentiment on Regulatory Compliance:** The "clean" nature (no data integrity issues) of the recent Ankleshwar inspection reinforces confidence in Zydus's manufacturing compliance, a critical factor for Indian pharma companies exporting to the US.

---

## 4) Latest Analyst Targets & Ratings

The following table summarizes the latest available price targets from major brokerages and consensus estimates.

Brokerage / Source	Rating	Target Price (INR)	Date of Report	Notes
Systematix Inst. Equities	BUY	1,038	Jan 20, 2026	Upgraded post-Zycubo approval
Macquarie	BUY	1,110	Jan 13, 2026	Maintained positive stance
Consensus Estimate	HOLD/ACCUMULATE	1,013 - 1,041	Jan 25, 2026	Average of ~30 analysts
ICICI Securities	HOLD	~910	Prev. Report	Conservative estimates
Prabhudas Lilladhar	ACCUMULATE	~970	Prev. Report	Value pick in pharma

**Disclaimer:** Market data and analyst targets are dynamic. Please conduct your own due diligence before making investment decisions.


# Stock Detailed Analysis Report

**ZYDUSLIFE.NS**

Current Price: ₹882.00

Generated: 2026-01-24 18:27

# ZYDUSLIFE.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	18.68%	15.04%
Net Income	Yes	Yes	17.26%	0.28%
ROE	No	Yes	-2.93%	-10.55%
EPS	Yes	Yes	17.91%	0.86%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	2.81%	2.59%
Net Income	Yes	25.27%	4.04%
ROE	Yes	17.08%	17.08%
EPS	No	12.25%	-11.77%

# ZYDUSLIFE.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Emerging Leader
RS Score:	47.5/100
:	

## == RS RATIOS ==:

1M RS:	1.014 [Leader]
3M RS:	0.913 [Neutral]
6M RS:	0.937 [Neutral]
1Y RS:	0.922 [Neutral]
:	


## == TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


## SIGNAL CRITERIA::

✓ Emerging RS:	1M (1.014) > 3M (0.913)
✓ Medium-term Lagging:	6M=0.937, 1Y=0.922 ( $\leq 1.0$ )
✗ Performance Improving:	Not improving


**Relative Strength Analysis: ZYDUSLIFE.NS vs ^CNXPHARMA**  
**Classification: Emerging Leader**  
**Price Performance Comparison (Normalized)**



**RS Ratio Trends (Multiple Timeframes)**



**RS Composite Score Timeline**



## ZYDUSLIFE.NS - EMA Crossover Summary


**EMA 20:** 894.88

**EMA 50:** 915.95

**EMA 200:** 944.76

**Trend Status:** **Strong Downtrend**

# ZYDUSLIFE.NS EMA Crossover Analysis



## ZYDUSLIFE.NS - Bollinger Bands Summary

<b>Current Price:</b>	882.00
<b>Upper Band:</b>	935.81
<b>Middle Band (SMA 20):</b>	898.24
<b>Lower Band:</b>	860.66
<b>%B:</b>	0.2839
<b>Band Width:</b>	0.0837
<b>Status:</b>	Lower Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<a href="#">Buy Signal at 2025-11-07 00:00:00+05:30</a>
<b>Recent Signal 2:</b>	<a href="#">Buy Signal at 2025-12-18 00:00:00+05:30</a>
<b>Recent Signal 3:</b>	<a href="#">Buy Signal at 2026-01-13 00:00:00+05:30</a>


## ZYDUSLIFE.NS Bollinger Bands (20, 2) Analysis



## ZYDUSLIFE.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	920.17
Signal Identified On:	2025-09-26

### Supertrend Analysis for ZYDUSLIFE.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## ZYDUSLIFE.NS - MACD Summary

<b>MACD Line:</b>	-12.19
<b>Signal Line:</b>	-11.22
<b>Histogram:</b>	-0.97
<b>Trend:</b>	<b>Bearish</b>
<b>Momentum:</b>	<b>Weakening</b>
<b>Signal:</b>	None

## ZYDUSLIFE.NS Price




## ZYDUSLIFE.NS MACD (12, 26, 9)



## ZYDUSLIFE.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.0837
<b>ATR:</b>	18.0214
<b>Total Signals:</b>	36
<b>Signal 1:</b>	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr)
<b>Signal 2:</b>	BB Squeeze + ATR Contraction at 2026-01-06 00:00:00+05:30 (Pr)
<b>Signal 3:</b>	BB Squeeze + ATR Contraction at 2026-01-07 00:00:00+05:30 (Pr)
<b>Signal 4:</b>	BB Squeeze + ATR Contraction at 2026-01-08 00:00:00+05:30 (Pr)
<b>Signal 5:</b>	<b>BB Squeeze (Bearish Breakout) at 2026-01-09 00:00:00+05:30</b>




## ZYDUSLIFE.NS - Volatility Squeeze Analysis



## ZYDUSLIFE.NS - RSI-Volume Summary

<b>Current RSI:</b>	40.10
<b>Current Volume:</b>	460331
<b>Volume MA 20:</b>	550224
<b>Bullish Divergences:</b>	6
<b>Bearish Divergences:</b>	3
<b>Bullish Div 1:</b>	Date: 2025-11-21 00:00:00+05:30, Price: 924.30
<b>Bullish Div 2:</b>	Date: 2025-12-18 00:00:00+05:30, Price: 913.65
<b>Bearish Div 1:</b>	Date: 2025-07-01 00:00:00+05:30, Price: 991.15
<b>Bearish Div 2:</b>	Date: 2025-09-18 00:00:00+05:30, Price: 1047.85

## ZYDUSLIFE.NS RSI-Volume Divergence Analysis



# ZYDUSLIFE.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

**Status:** 32 Signals Detected

:

**2025-12-24 [-]:** Distribution Day



**2025-12-30 [-]:** Distribution Day

**2026-01-07 [-]:** Distribution Day

**2026-01-09 [-]:** Distribution Day

**2026-01-20 [-]:** Distribution Day

## ZYDUSLIFE.NS - Volume Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	941.44	882.0	2025-11-03
1 Day	DOWNTREND (Sell)	920.17	882.0	2025-09-26
15 Min	DOWNTREND (Sell)	891.41	886.0	2026-01-23

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	No Signal
1 Day	Bearish	Weakening	No Signal
15 Min	Bearish	Weakening	No Signal

# ZYDUSLIFE.NS - 1 Week (Candlestick + EMAs)



# ZYDUSLIFE.NS - 1 Day (Candlestick + EMAs)



# ZYDUSLIFE.NS - 15 Min (Candlestick + EMAs)



## Trendlyne Snapshot - ZYDUSLIFE\_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)  Search Stock, IPO, MF [India](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [ZYDUS LIFESCIENCES LTD.](#)

### Zydus Lifesciences Ltd. [①](#)

NSE: ZYDUSLIFE | BSE: 532321  
Zydus Lifesciences Live Share Price Today, Share Analysis and Chart

■ ■ ■ Falling Comet [②](#) ● In 4 Starfolio Baskets

**882.00** -3.30 (-0.37%)

**484.6K** NSE+BSE Volume  
NSE 23 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score [①](#) **65.0 /100**  
High Financial Strength [②](#)

Falling Comet These stocks have good quality scores. However, their weak technicals make them more bearish

Valuation Score [①](#) **43.7 /100**  
Mid Valuation [②](#)

Momentum Score [①](#) **34.0 /100**  
Technically Bearish [②](#)

Analyst Price Target [①](#) **1,014**  
1Yr Price target upside is 15%

[DVM](#)  
[Key Metrics](#)  
[Price Chart](#)  
[Forecaster](#)  
[Financials](#)  
[Technical](#)  
[Shareholding](#)  
[Deals](#)  
[Documents](#)  
[Corporate actions](#)  
[Company Profile](#) X

#### Check Before You Buy

High rank **18** 5 Positive \* 16 Negative 3 Negative **69.6% Pass in checklist**

[VIEW FULL CHECKLIST](#)

#### PE Valuation Check

Right Now [①](#) Undervalued **26.6%**  
1 Year Forward [①](#) Undervalued **17.6%**

**INSIGHT** Zydus Lifesciences is undervalued at both current PE and future earnings estima

#### Zydus Lifesciences Key Metrics

ROE Ann. % <a href="#">①</a> High in Industry	<b>18.9</b>	Broker Average Target <a href="#">①</a> 17.97% upside	<b>1,040.5</b>	Market Capitalization <a href="#">①</a> High in Industry	<b>88,749.8</b>	Price to Book <a href="#">①</a> Above Industry Median
--	-------------	--	----------------	---	-----------------	--

## Trendlyne Snapshot - ZYDUSLIFE\_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [ZYDUSLIFESCIENCES LTD.](#)

**Zydus Lifesciences Ltd.** ⓘ

NSE: ZYDUSLIFE | BSE: 532321

■ ■ ■ Falling Comet ⓘ ● In 4 Starfolio Baskets

**882.00** -3.30 (-0.37%)

**484.6K** NSE+BSE Volume

NSE 23 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

### Zydus Lifesciences - ZYDUSLIFE - stock price prediction, stock forecast, target price, analyst ratings from 30 analysts

Zydus Lifesciences has a share price target of Rs 1014, revenue growth forecast of 10.6%, and profit growth estimate of 2.9% for FY26, based on top 30 analyst calls.

### Zydus Lifesciences FORECASTER - Analyst Estimates ⓘ

[FORECASTER DASHBOARD →](#)

